Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors

BACKGROUND AND OBJECTIVE: Population pharmacokinetic analysis explored the pharmacokinetics of sunitinib and its primary active metabolite, SU012662, in children and evaluated the sunitinib dose(s) that produce comparable plasma exposures to adults receiving the approved daily dose. METHODS: Data we...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Erjian, DuBois, Steven G., Wetmore, Cynthia, Verschuur, Arnauld C., Khosravan, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093178/
https://www.ncbi.nlm.nih.gov/pubmed/33852135
http://dx.doi.org/10.1007/s13318-021-00671-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093178/
https://www.ncbi.nlm.nih.gov/pubmed/33852135
http://dx.doi.org/10.1007/s13318-021-00671-7

Ejemplares similares